Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine maintenance after allo-HSCT for MRD-positive AML or MDS
ChiCTR1900024518Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Complete remission state of bone marrow, Remission state of hematology and 4 more. Started Aug 2019; status: recruiting.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1900024518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024518.